IMMUNITYBIO, INC. Finance Lease, Liability, Current
IMMUNITYBIO, INC. (IBRX) had Finance Lease, Liability, Current of $55.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Debt, Current
us-gaap:FinanceLeaseLiabilityCurrent · last filed 2026-08-04
- 2026-06-30: Finance Lease, Liability, Current $55.00K.
- 2026-03-31: Finance Lease, Liability, Current $53.00K.
- 2025-12-31: Finance Lease, Liability, Current $52.00K.
- 2025-09-30: Finance Lease, Liability, Current $50.00K.
| Period end | Finance Lease, Liability, Current |
|---|---|
| 2026-06-30 | $55.00K 10-Q · filed 2026-08-04 |
| 2026-03-31 | $53.00K 10-Q · filed 2026-05-07 |
| 2025-12-31 | $52.00K 10-Q · filed 2026-08-04 |
| 2025-09-30 | $50.00K 10-Q · filed 2025-11-05 |
| 2025-06-30 | $49.00K 10-Q · filed 2025-08-05 |
| 2024-12-31 | $0.00 10-K · filed 2026-02-23 |
| 2024-09-30 | $0.00 10-Q · filed 2024-11-12 |
| 2024-06-30 | $22.00K 10-Q · filed 2024-08-12 |
| 2024-03-31 | $43.00K 10-Q · filed 2024-05-09 |
| 2023-12-31 | $64.00K 10-K · filed 2025-03-03 |
| 2023-09-30 | $84.00K 10-Q · filed 2023-11-09 |
| 2023-06-30 | $81.00K 10-Q · filed 2023-08-08 |
| 2023-03-31 | $79.00K 10-Q · filed 2023-05-11 |
| 2022-12-31 | $77.00K 10-K · filed 2024-03-19 |
| 2022-09-30 | $75.00K 10-Q · filed 2022-11-09 |
| 2021-12-31 | $0.00 10-K · filed 2023-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |